Life Sciences

life sciences industry

Today’s life sciences industry faces myriad challenges, including complex regulation, steep competition and ever-changing technologies. Companies around the world turn to Ropes & Gray’s global life sciences group for internationally recognized counsel on virtually all matters impacting their businesses.

Contact

“A fact repeatedly pointed out- the firm maintains a stellar reputation for expertise across regulatory and transactional law.” LMG Life Sciences
“A distinguishing characteristic of Ropes & Gray is the degree to which the firm’s corporate capabilities combine with deep experience in regulatory matters and government investigations. Their team is broad and deep and they have shown a terrific willingness to deliver cost-effective service in unique ways.” LMG Life Sciences
“We get great outcomes from them because of their way of working. It's very collaborative; they are easy to work with, there is a minimum of drama and they are enormously dedicated and seem to have a culture of total client devotion.” Client, LMG Life Sciences

Overview

The attorneys and technical specialists who make up the global life sciences group understand the unique needs of a wide range of clients in the dynamic life sciences industry. We work across practices and geographies to develop cutting-edge solutions that help our clients meet their business goals.

In addition to advising biotechnology, pharmaceutical and medical device companies, we also work with:

Drawing on resources in our offices around the globe, we focus on developing cutting-edge solutions to help clients meet their business goals. Our practice includes:

Experience

Ropes & Gray’s life sciences team has handled every type of transaction from licensing agreements with a small biotechnology company to large mergers of industry-leading pharmaceutical and medical device companies around the globe. Recent noteworthy transactions include representation of:

  • Shire in its agreement with Baxalta Incorporated to combine the companies for an aggregate consideration of approximately $32 billion. Baxalta, headquartered in Northern Illinois, is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology, and immunology.
  • Akebia Therapeutics in multiple transformative transactions, totaling an aggregate of nearly $2 billion, through which Akebia partnered its lead drug candidate in key markets, secured financing for completing its Phase III clinical trials, and in-licensed a library of compounds for future research and development.
  • Zai Lab Limited, a Chinese-based biotechnology company, in its Series A, B and C preferred equity financings, in which Zai Lab raised an aggregate of $165 million, and in its subsequent $172.5 million initial public offering.
  • Pfizer on its $14 billion acquisition of Medivation Inc., a biopharmaceutical company focused on developing and commercializing small molecules for oncology.
  • Bain Capital in its $55 million Series D financing and investment rounds for InflaRx, a German biopharmaceutical company, and in its $70 million convertible preferred PIPE investment in Dicerna Pharmaceuticals, a leading developer of RNAi therapeutics.
  • Vertex Pharmaceuticals in its co-development and co-commercialization of CTX001, an investigational gene editing treatment, with CRISPR Therapeutics. The agreement is part of the companies’ previously announced $2.6 billion collaboration aimed at the discovery and development of new gene editing treatments that use the CRISPR/Cas9 technology.
  • Boehringer Ingelheim in a $595 million global license and collaboration agreement with AbbVie to jointly develop and commercialize a biologic IL-23 antibody for the treatment of psoriasis and other immunological indications.
  • Pacira Pharmaceuticals in First Amendment and APA challenges to FDA’s assertions that the company engaged in “off-label” promotion of its flagship product, a post-surgical analgesic.  As a result, FDA agreed to withdraw its warning letter and revise the label to clarify that the challenged claims were permissible.
  • Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, in its $65 million definitive license agreement with GE Healthcare for the continued Phase III development and worldwide commercialization of flurpiridaz F 18.
  • Mersana Therapeutics, a clinical-stage biopharmaceutical company, in connection with its $75 million initial public offering.  
Cookie Settings